Freenome, Inc. - Common stock (FRNM)

11.15
+1.16 (11.61%)
NASDAQ· Last Trade: Aug 1st, 3:37 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
– Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening –
By Freenome, Inc. · Via GlobeNewswire · July 27, 2026